Intensity Therapeutics, Inc. Common Stock

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement